Epidemiological trends of multidrug-resistant organisms in a tertiary-care pediatric hospital, 2017–2023 Authors: Carmen D’Amore, Paola Bernaschi, Gaetano Ciliento, Flavia Beccia, Leonardo Villani, Benedetta Zama, Elisa Cappelli, Lucilla Ravà, Carlo Federico Perno, Massimiliano Raponi, Marta Ciofi degli Atti Published: 2026 ABSTRACT AbstractBackgroundAntimicrobial resistance (AMR) is a growing global threat, particularly for children under 5 years. This study is aimed to investigate temporal trends and describe the epidemiological characteristics of MDR bacteria isolated in hospitalized children from 2017 to 2023 in an academic children’s hospital in Italy.MethodsWe included all bacterial isolates obtained from blood or cerebrospinal fluid (CSF) cultures collected from pediatric patients evaluated in both inpatient settings and the Emergency Department between 1 January 2017 and 31 December 2023. The study included the main ESKAPE pathogens (including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa) and other relevant MDROs such as Escherichia coli. Data were extracted from the hospital microbiology data warehouse, and resistance proportions were calculated as MDR isolates over total isolates for each pathogen. Associations between year, patient characteristics, ward type, and MDRO infections were evaluated using univariable and multivariable logistic regression; trends over time were evaluated using the Cochrane-Armitage test for categorical variables.ResultsOut of 51,886 blood or CSF cultures, 1,528 (2.9%) were positive for microorganisms of interest, and 211 (13.8%) were MDROs. The highest resistance proportions were observed in Carbapenems-Resistant Pseudomonas Aeruginosa/Pseudomonas Aeruginosa (CRPA/PA, 52.8%), followed by Methicilln-Resistant Staphylococcus Aureus/Staphylococcus Aureus (MRSA/SA, 36.7%), Carbapenem-Resistant Klebsiella Pneumoniae/Klebsiella Pneumoniae (CRKP/KP, 12.6%), and Vancomycin-Resistant Enterococcus (VRE)/Enterococcus (VRE/E, 11.5%). Significant reductions were recorded for MRSA/SA (43.5% in 2017 to 25.7% in 2023; p = 0.001) and CRPA/PA (85.0% to 47.1%; p < 0.001), while CRKP/KP and VRE/E showed no significant temporal trends. Neonatology and PICU showed higher odds for MRSA isolation (p < 0.001) compared to medical wards. Onco-hematology displayed an adjusted OR of 3.0 (95% CI: 1.2–7.7) for VRE. Year was independently associated with CRPA, with adjusted ORs of 0.03 and 0.14 in 2020 and 2021 (p < 0.01) compared to 2017.ConclusionsUnderstanding local AMR patterns remains essential for guiding empirical therapy across heterogeneous hospital settings.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13052-026-02300-y.Keywords: Antimicrobial resistance, Epidemiology, Pediatrics, Hospital Background Bacteria antimicrobial resistance (AMR) is characterized by the ability of bacteria to withstand the effects of antibiotics, and is a significant and rapidly evolving threat to public health globally [1]. The emergence of multidrug resistance (MDR), where bacteria exhibit resistance to three or more types of antibiotics [2], further exacerbates the challenge of treating infectious diseases [3, 4]. AMR poses a profound threat to public health, with 1.14 million direct deaths and 4.71 million associated deaths in 2021, alongside 42.6 million attributable Disability‑Adjusted Life Years [5]. This burden is so significant that the World Health Organization (WHO) has included it among the 10 health threats to humanity, underscoring the need for coordinated action embracing a One Health approach [6]. The six priority pathogens responsible for these deaths include Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Methicillin-resistant S. aureus alone caused over 100,000 estimated deaths [7]. In European Union (EU), Iceland and Norway, more than 35,000 people die from infections with bacteria that are resistant to antimicrobials each year and, among these, approximately one third occur in Italy [8]. Indeed, Italy ranks among the first Countries in EU for the high prevalence of AMR bacteria [9]; in 2024, 25.7% of Staphylococcus aureus isolates form sterile sites were methicillin-resistant (MRSA), and 24.0% of Klebsiella pneumoniae were resistant to carbapenems (CRKP), compared to EU means of 14.2% and 11.3% respectively [10]. The COVID-19 pandemic, declared by WHO from 11 March 2020 to 5 May 2023 [11], disrupted the epidemiology of several infectious diseases, and had the potential to impact the burden of AMR bacteria, whose emergence and circulation can be affected by changes in antibiotic use, public health interventions and infection prevention measures [12, 13]. A systematic review documented an increase in the rate of multidrug resistant gram-positive and gram-negative bacteria during the COVID-19 pandemic [14], while other authors reported a decrease of MDR organisms (MDROs) rates among hospitalized patients [15]. Children, especially those under 5 years old, face a relevant risk of AMR-related complications [16–18]. In 2019, it was estimated that 254,000 children under 5 died from AMR, representing about 20% of the total 1.27 million AMR deaths globally [19]. Beyond the immediate health consequences, the long-term impact of AMR on children is concerning. AMR can lead to impaired child development, loss of family earnings due to child hospitalizations, inconsistent school attendance, and higher toxicity from second-line antimicrobials causing lifelong disability [19]. Also the economic impact of AMR is significant for both healthcare systems and individual hospitals [20–21], especially in children [22], underscoring the need to develop robust surveillance and monitoring systems to identify pathogens and related diseases, and to implement preventive strategies aimed at reducing its burden [23]. This study is aimed to investigate temporal trends and describe the epidemiological characteristics of MDR bacteria isolated in hospitalized children from 2017 to 2023 in an academic children’s hospital in Italy. Methods Study setting This study was conducted at the Bambino Gesù Children’s Hospital (Ospedale Pediatrico Bambino Gesù, OPBG), a 627-bed Academic hospital located in the Lazio Region, Italy. From 2007, a series of actions to improve practices for healthcare-associated infections prevention and control were implemented, including screening for Carbapenem-Resistant Enterobacteriaceae (CRE) or MRSA colonization through rectal and nasal swabs in patients hospitalized in intensive care units and other high-risk units (e.g. transplant units, onco-hematology units), on admission and discharge. During hospitalization in these units, patients continued to be screened for CRE and MRSA on a regular basis. In case of occurrence of infections due to MDR, all patients hospitalized in the same ward were screened for MDR. Mupirocin decolonization was performed in case of MRSA nasal carriers. Contact precautions were adopted for patients identified as CRE or MRSA positive together with antiseptic hand hygiene, use of gloves, gowns, single rooms or cohort, and dedicated patient equipment. Adoption of contact precautions was actively verified by the Infection Control Committee team and notified on the patient room door and in clinical records. Patients and their caregivers received written information regarding precautions to be adopted after discharge [24]. During the pandemic period, infection prevention and control measures were enforced. Emergency Department (ED) flows were organized to separate children with fever and respiratory symptoms from other patients. All patients and their parents were actively screened when entering the hospital using a structured questionnaire checking for fever, respiratory symptoms and possible contacts with COVID-19 cases, only one parent or relative per patient was allowed to enter the hospital [25]. The use of masks had been implemented throughout the hospital. These specific restrictive COVID measures were reduced at the end of the pandemic period (5th May 2023) with the exception of the use of FFP2 masks, which is currently still required for healthcare personnel, family members, visitors, and patients (with the exception of children under 6 years of age and those with medical conditions or disabilities incompatible with the use of masks) in the ED, in same clinical wards (e.g. intensive care units, oncohematological wards) or in case of caring for immunosuppressed patients or patients with symptoms compatible with respiratory infections. Inclusion and exclusion criteria We included all bacterial isolates obtained from blood or cerebrospinal fluid (CSF) cultures collected from pediatric patients evaluated in both inpatient settings and the ED between 1 January 2017 and 31 December 2023. The study included the main ESKAPE pathogens [26] (including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa) and other relevant MDROs such as Escherichia coli. Isolates regarding the same MDRO from the same patient within a 14-day interval were excluded from the analysis, based on the assumption that treatment for invasive infections due to MDR bacteria may require up to 14 days [27, 28]. Data collection Data were extracted from the hospital microbiology data warehouse. The collected information included patient unique identifier, age, sex, date of admission, type of ward, date of microbiology test, type of culture material (blood/CSF), type of microorganism cultured and results of antibiograms with Minimum Inhibitory Concentrations (MICs). Definitions of MDROs were based on international consensus criteria [3] as organisms non‑susceptible to at least one agent in three or more antimicrobial classes or meeting criteria for extensively drug-resistant (XDR) phenotypes. Antimicrobial susceptibility testing was performed according to EUCAST criteria [29]. Extensively drug‑resistant Pseudomonas aeruginosa (XDRPA), defined as strains susceptible to only one or two of the following antimicrobial classes (aminoglycosides, antipseudomonal carbapenems, antipseudomonal cephalosporins, antipseudomonal fluoroquinolones, antipseudomonal penicillins plus β‑lactamase inhibitors, monobactams, phosphonic acids and polymyxins). Multidrug-resistant Pseudomonas aeruginosa (MDRPA) is defined as non-susceptibility to at least one agent in three or more of the following antimicrobial classes: antipseudomonal cephalosporins, antipseudomonal penicillins/β-lactamase inhibitor combinations (e.g., piperacillin–tazobactam), carbapenems, fluoroquinolones, and aminoglycosides. Extensively drug‑resistant Acinetobacter baumannii (XDRAB), defined as strains susceptible to only one or two of the following antimicrobial classes: aminoglycosides, antipseudomonal carbapenems, antipseudomonal fluoroquinolones, antipseudomonal penicillins plus β‑lactamase inhibitors, extended‑spectrum cephalosporins folate pathway inhibitors, penicillins plus β‑lactamase inhibitors, polymyxins and tetracyclines. Multidrug-resistant Acinetobacter baumannii (MDRAB), defined as resistant to at least two of the following antibiotic classes: antipseudomonal cephalosporins, fluoroquinolones, aminoglycosides, and β-lactam/β-lactamase inhibitor combinations (piperacillin–tazobactam, ampicillin–sulbactam). Carbapenem-resistant organisms were defined as isolates non-susceptible to at least one carbapenem agent. Accordingly, carbapenem-resistant Acinetobacter baumannii (CRAB), Escherichia coli (CREC), Klebsiella pneumoniae (CRKP), and Pseudomonas aeruginosa (CRPA) were identified as isolates non-susceptible to at least one carbapenem (e.g., imipenem, meropenem, doripenem, and, for Enterobacterales, ertapenem). Vancomycin-resistant Enterococci (VRE), including Enterococcus faecalis and Enterococcus faecium, were defined based on resistance to vancomycin as determined by routine susceptibility testing. For MRSA, methicillin resistance was coded based on resistance to β-lactam anti-staphylococcal agents (oxacillin). Statistical analysis Cultures were described by type of culture materials, year of isolation, sex and age classes, and type of ward requiring the exam. Type of ward was recoded into six categories: medical wards, surgical wards, onco-hematology, pediatric intensive care units (PICUs), neonatology (i.e. neonatal intensive care unit NICU, neonatal surgery, neonatal semi-intensive care), and ED. Proportion of resistant was calculated as the ratio of MDR isolates to the total samples of each microorganism. Annual incidence rates for MDRO invasive infections were calculated by dividing the number of infections by days of hospitalizations. The association between year, patient characteristics, ward of hospitalization, and proportion of MDRO infections was assessed using univariable analysis and multivariable logistic regression models. Variables were selected for inclusion in the multivariable logistic regression model based on univariate analysis results and clinical relevance. Variables not statistically significant in univariate analysis were excluded. Crude and adjusted odds ratios (OR), with 95% confidence intervals (CI) were estimated. Trends over time were evaluated using the Cochrane-Armitage test for categorical variables; temporal trends of incidence rates for MDRO per 100,000 patient days were tested using Poisson regression. Statistical significance was set at p-values < 0.05. For statistical analysis, only MDROs that were isolated in at least 20 cases were included, while any MDRO isolated fewer than 20 times was excluded from statistical elaboration. Statistical analysis was performed using STATA 18 (Stata Corporation, College Station, Texas, USA). Results From 1st January 2017 to 31st December 2023, there were 64,437 requests for bacterial cultures from blood or CSF in OPBG inpatients; 12,551 cultures were excluded because conducted within 14 days of a previous culture with identical results in the same patient, resulting in 51,886 cultures included in the analysis. Blood cultures accounted for 94.4% of total of cultures performed during the study period. The distribution of cultures by year increased from 13.5% (6,985/51,886) in 2017 to 15.4% (7,969/51,886) in 2023; the majority of cultures were from male patients (29,371/51,886; 56.6%), aged between one and four years (13,325/51,886; 25.7%), and hospitalized in onco-hematology (18,014/51,886; 34.7%) or medical wards (14,793/51,886; 28.5%) at the time of the exam request (Table 1). Table 1Descriptive analysis of blood/CSF microbiological cultures for selected microorganism; OPBG, 2017–2023VariableCategoriesNumber of culturesNumber of cultures tested positive for selected microorganisms^ (both resistant and sensitive)** P-value Number of cultures tested positive for MDROs*** P-value N = 51,886N = 1,528(%)N = 211(%)MaterialCSF2,91135(1.2) < 0.001 13(37.1) < 0.001 Blood48,9751,493(3.0)198(13.3)Year20176,985208(3.0) 0.014* 36(17.3) 0.017* 20187,333241(3.3)45(18.7)20197,455237(3.2)35(14.8)20207,352242(3.3)25(10.3)20217,648192(2.5)20(10.4)20227,144189(2.6)17(9.0)20237,969219(2.7)33(15.1)SexFemale22,515689(3.1) 0.182 83(12.0) 0.07 Male29,371839(2.9)128(15.3)Age<29d3,924149(3.8) < 0.001 10(6.7) < 0.001 29d-1y10,404623(6.0)62(10.0)1-4y13,325328(2.5)50(15.2)5-9y9,466154(1.6)19(12.3)10-14y7,617132(1.7)34(25.8)>=15y7,150142(2.0)36(25.4)Type of wardMedical14,793540(3.7) < 0.001 43(8.0) < 0.001 Surgical2,84472(2.5)11(15.3)Oncohematology18,014164(0.9)50(30.5)PICU8,294322(3.9)72(22.4)Neonatology6,929413(6.0)34(8.2)ED1,01217(1.7)1(5.9)^ Staphylococcus aureus (Methicillin-Resistant, MRSA), Acinetobacter baumannii (Multidrug and Carbapenems-Resistant, MDRAB, CRAB), Escherichia coli (Carbapenems-Resistant, CREC), Klebsiella pneumoniae (Carbapenems-Resistant, CRKP), Pseudomonas aeruginosa (Carbapenems-Resistant, CRPA, Multidrug-Resistant MDRPA, Extensively drug-resistant XDRPA), and Enterococcus (Vancomycin-Resistant, VRE)*Cochran-Armitage test for trend** Percentages represent the proportion of cultures positive for selected microorganisms (both resistant and susceptible) out of the total number of cultures*** Percentages represent the proportion of cultures tested positive for MDROs out of the number of cultures positive for selected microorganisms (both resistant and susceptible) Descriptive analysis of blood/CSF microbiological cultures for selected microorganism; OPBG, 2017–2023 ^ Staphylococcus aureus (Methicillin-Resistant, MRSA), Acinetobacter baumannii (Multidrug and Carbapenems-Resistant, MDRAB, CRAB), Escherichia coli (Carbapenems-Resistant, CREC), Klebsiella pneumoniae (Carbapenems-Resistant, CRKP), Pseudomonas aeruginosa (Carbapenems-Resistant, CRPA, Multidrug-Resistant MDRPA, Extensively drug-resistant XDRPA), and Enterococcus (Vancomycin-Resistant, VRE) *Cochran-Armitage test for trend ** Percentages represent the proportion of cultures positive for selected microorganisms (both resistant and susceptible) out of the total number of cultures *** Percentages represent the proportion of cultures tested positive for MDROs out of the number of cultures positive for selected microorganisms (both resistant and susceptible) Out of the total 51,886 blood or CSF cultures, 1,528 (2.9%) were positive for microorganisms of interest, independently from their bacterial-resistance profile. The rate of positive cultures for microorganisms of interest (independently from their bacterial-resistance profile) out of the total number of cultures was higher in blood (1,493/48,975; 3.0%) with respect to CSF (35/2,911; 1.2%; p < 0.001), in patients aged 29d-1y (623/10,404, 6.0%; p < 0.001) and hospitalized in Neonatology (413/6,929, 6.0%; p < 0.001). Trend of isolates proportion for selected microrganisms out of the total number of cultures by year decreased from 3.0% (208/6,985) in 2017 to 2.7% (219/7,969) in 2023 (p for trend: 0.014). No differences were observed in the rate of positivity by sex (Table 1). Out of 1,528 (2.9%) samples positive for microorganisms of interest (both resistant and sensitive), 211 (13.8%) were positive for MDROs. MDROs were isolated more frequently in CSF fluid (13/35; 37.1%) with respect to blood samples (198/1,493, 13.3%, p < 0.001), in patients aged more than ten years (p < 0.001) and hospitalized in Oncohematology (50/164, 30.5%; p < 0.001, Table 1). Proportion of cultures positive for MDROs, calculated over the total number of cultures positive for the selected microorganisms (including both resistant and susceptible isolates) by year decreased from 17.3% (36/208) in 2017 to 15.1% (33/219) in 2023 (p for trend: 0.017). No differences were observed in the rate of positivity by sex (Table 1). Characterization of MDROs Over the study period, the most frequent MDRO was MRSA (n = 177), followed by CRPA (n = 93), VRE (n = 53) and CRKP (n = 20). Seventeen cases of MDRAB or CRAB were registered: 13 isolates were both MDRAB and CRAB, 2 cases were MDRAB only and 2 cases were CRAB only. Moreover, three cases of CREC were registered. Table 2 describes characteristics of MDROs with ≥ 20 isolates. The proportion of MDROs by type of microorganism isolated was higher for CRPA (93/176; 52.8%), followed by MRSA (177/482; 36.7%), CRKP (20/159; 12.6%) and VRE (53/460; 11.5%). The proportion of MRSA and CRPA significantly decreased over the years from 43.5% in 2017 to 25.7% in 2023 (p = 0.001) and from 85.0% in 2017 to 47.1% in 2023 (p < 0.001), respectively; whereas no significant trends were observed for CRKP and VRE. No differences in proportion of MDROs by sex were observed; MRSA and CRPA significantly varied by age and type of ward, and CRKP by age. The proportion of MRSA peaked in infants ≤ 1 year of age and then decreased with increasing age; it was highest in Neonatology and PICU compared to other wards. The proportion of CRPA was highest in 10–14 year old children and in onco-hematology, compared to other age groups and type of wards. CRKP was most frequent in children ≥ 10 years (Table 2). Table 2Prevalence and trends of selected microorganisms isolatesMRSA/SACRKP/KPCRPA/PAVRE/EN(%)*N(%)**N(%)***N(%)**** Resistance 177/482(36.7)20/159(12.6)93/176(52.8)53/460(11.5) Material CSF4/6(66.7)1/1(100)5/8(62.5)3/14(21.4)Blood173/476(36.3)19/158(12.0)88/168(52.4)50/446(11.2) p-value 0.199 0.126 0.724 0.211 Year 201727/62(43.5)6/27(22.2)17/20(85.0)6/58(10.3)201837/76(48.7)3/27(11.1)30/31(96.8)5/64(7.8)201929/72(40.3)5/30(16.7)11/26(42.3)8/69(11.6)202032/86(37.2)2/23(8.7)3/27(11.1)9/71(12.7)202114/59(23.7)0/14(0.0)9/21(42.9)8/65(12.3)202219/53(35.8)0/17(0.0)7/17(41.2)8/70(11.4)202319/74(25.7)4/21(19.1)16/34(47.1)8/63(12.7) p−value trend 0.0014 0.2448 < 0.0001 0.5830 Sex Female77/220(35.0)9/76(11.8)38/78(48.7)19/200(9.5)Male100/262(38.2)11/83(13.2)55/98(56.1)34/260(13.1) p-value 0.472 0.816 0.328 0.234 Age class <29d20/40(50.0)1/16(6.3)2/4(50.0)6/60(10.0)29d-1y108/194(55.7)6/85(7.1)23/44(52.3)24/201(11.9)1-4y29/100(29.0)5/30(16.7)22/49(44.9)9/97(9.3)5-9y9/65(13.9)1/7(14.3)6/18(33.3)5/41(12.2)10-14y7/49(14.3)5/15(33.3)21/26(80.8)3/27(11.1)>=15y4/34(11.8)2/6(33.3)19/35(54.3)6/34(17.7) p-value < 0.001 0.027 0.032 0.848 Type of ward Medical39/219(17.8)4/33(12.1)18/51(35.3)11/123(8.9)Surgical7/28(25.0)1/2(50.0)9/15(60.0)1/13(7.7)Oncohematology2/11(18.2)5/18(27.8)23/31(74.2)15/75(20.0)PICU31/76(40.8)7/48(14.6)35/61(57.4)8/95(8.4)Neonatology97/143(67.8)3/56(5.3)7/16(43.8)18/154(11.7)ED1/5(20.0)0/2(0.0)1/2(50.0)0/0(0.0) p-value < 0.001 0.075 0.013 0.158 *Percentages represent the proportion of resistant isolates, calculated as MRSA/total S. aureus (SA)**Percentages represent the proportion of resistant isolates, calculated as carbapenem-resistant Klebsiella pneumoniae (CRKP)/total K. pneumoniae (KP)***Percentages represent the proportion of resistant isolates, calculated as carbapenem-resistant Pseudomonas aeruginosa (CRPA)/total P. aeruginosa (PA)**** Percentages represent the proportion of resistant isolates, calculated as vancomycin-resistant Enterococcus (VRE)/total Enterococcus (E) Prevalence and trends of selected microorganisms isolates *Percentages represent the proportion of resistant isolates, calculated as MRSA/total S. aureus (SA) **Percentages represent the proportion of resistant isolates, calculated as carbapenem-resistant Klebsiella pneumoniae (CRKP)/total K. pneumoniae (KP) ***Percentages represent the proportion of resistant isolates, calculated as carbapenem-resistant Pseudomonas aeruginosa (CRPA)/total P. aeruginosa (PA) **** Percentages represent the proportion of resistant isolates, calculated as vancomycin-resistant Enterococcus (VRE)/total Enterococcus (E) The multivariable analysis showed that type of ward was significantly and independently associated with risk of MRSA and VRE (Table 3). Neonatology and PICU adjusted ORs were respectively 6 and 3 for MRSA compared to medical wards (p < 0.001), whereas oncohematology had an adjusted ORs of 3.0 (CI 95%: 1.2–7.7) for VRE. Year was significantly and independently associated to CRPA risk, with adjusted ORs of 0.03 and 0.14 in 2020 and 2021 compared to 2017 (p < 0.01). Table 3Univariable and multivariable regression models results for MRSA, VRE, CRKP and CRPAMRSAVRECRKPCRPAOR unadj (95%CI)OR adj(95%CI)OR unadj(95%CI)OR adj(95%CI)OR unadj(95%CI)OR adj(95%CI)OR unadj(95%CI)OR adj(95%CI) Year – Ref: 2017 1 1 1 1 1 1 1 1 20181.2 (0.6–2.4)1.5 (0.7–3.4)0.9 (0.3–2.9)0.9 (0.3–2.9)0.4 (0.1–1.9)0.3 (0.1–1.8)5.3 (0.5–54.9)8.5 (0.7-104.4)20190.9 (0.4–1.7)1.1 (0.5–2.3)1.1 (0.4–3.5)1.2 (0.4–3.8)0.7 (0.2–2.6)0.4 (0.1–1.8)0.1 (0.03–0.5)*0.2 (0.04–0.9)*20200.8 (0.4–1.5)0.8 (0.4–1.6)1.3 (0.4–3.8)1.3 (0.4–4.1)0.3 (0.1–1.8)0.1 (0.02–1.2)0.02 (0.004-0.1)**0.03 (0.0005-0.2)**20210.4 (0.2–0.9)*0.5 (0.2–1.2)1.2 (0.4–3.7)1.1 (0.4–3.7) - - 0.1 (0.03–0.6)*0.1 (0.02–0.7)*20220.7 (0.3–1.5)0.8 (0.3-2.0)1.1 (0.3–3.4)1.0 (0.3–3.3) - - 0.1 (0.02–0.6)*0.2 (0.04–1.1)20230.4 (0.2–0.9)*0.6 (0.3–1.4)1.3 (0.4–3.9)1.2 (0.4–3.9)0.8 (0.2–3.4)0.4 (0.1-2.0)0.2 (0.04–0.6)*0.2 (0.03–0.8)* Hospital ward – Ref: Medical OU 1 1 1 1 1 1 1 1 Surgical OU1.5 (0.6–3.9)2.4 (0.9–6.6)0.8 (0.1–7.1)0.8 (0.1–6.6)7.2 (0.4-140.2)5.1 (0.1-185.9)2.8 (0.8–8.9)1.8 (0.4–9.1)Oncohematology1.0 (0.2–4.9)1.5 (0.3–7.5)2.5 (1.1–5.9)*3.0 (1.2–7.7)*2.8 (0.6–12.1)1.8 (0.3–11.7)5.3 (1.9–14.2)**3.6 (1.0–13.0)PICU3.2 (1.8–5.6)**3.0 (1.7–5.5)**0.1 (0.4–2.4)0.9 (0.3–2.3)1.2 (0.3–4.6)1.3 (0.3-6.0)2.5 (1.1–5.3)*2.2 (0.8–5.6)Neonatology9.7 (5.9–15.9)**6.3 (3.4–11.7)**1.3 (0.6-3.0)1.0 (0.4–2.7)0.4 (0.1–1.9)0.5 (0.1–3.4)1.4 (0.4–4.5)0.8 (0.2–4.4)ED1.1 (0.1–10.6)1.4 (0.1–13.9)-- - - 1.8 (0.1–31.1)2.4 (0.02–245.0) Age class – Ref: <29d 1 1 1 1 1 1 1 1 29d-1y1.2 (0.6–2.5)1.7 (0.8–3.6)1.2 (0.5–3.1)1.3 (0.5–3.4)1.1 (0.1–10.1)0.9 (0.1–9.6)1.1 (0.1–8.5)4.3 (0.1-133.1)1-4y0.4 (0.2–0.9)*1.2 (0.5–2.9)0.9 (0.3–2.7)0.6 (0.2–2.5)3.0 (0.3–28.2)1.6 (0.1–20.9)0.8 (0.1–6.3)2.3 (0.07–79.2)5-9y0.2 (0.1–0.4)**0.5 (0.2–1.6)1.2 (0.3–4.4)0.8 (0.2–3.5)2.5 (0.1–46.8)0.7 (0.02–19.5)0.5 (0.05–4.5)1.6 (0.04–63.4)10-14y0.2 (0.1–0.5)**0.5 (0.2–1.5)1.1 (0.3–4.8)0.6 (0.1–3.5)7.5 (0.7–74.1)4.9 (0.3–73.5)4.2 (0.5–37.5)12.6 (0.3–470.8)>=15y0.1 (0.04–0.4)**0.4 (0.1–1.6)1.9 (0.6–6.5)1.1 (0.2–5.1)7.5 (0.5-105.3)4.5 (0.2–99.8)1.2 (0.15–9.4)3.3 (0.1-114.6)*p < 0.05; **p < 0.001 Univariable and multivariable regression models results for MRSA, VRE, CRKP and CRPA *p < 0.05; **p < 0.001 Incidence of MDROs per 100,00 inpatient days by years In the study period, annual inpatient days were 189,383 in 2017, 185,494 in 2018, 206,435 in 2019, 199,905 in 2020, 201,350 in 2021, 204,675 in 2022, and 209,214 in 2023. Annual MDRO incidence per 100,000 inpatient days is shown in Fig. 1. CRPA and MRSA had their highest incidence in 2018 (CRPA: 15.8/100,000; MRSA: 19.9/100,000), then decreased reaching lowest rates in 2020 and 2021, respectively (CRPA: 1.58; MRSA: 7.5), followed by an increase in 2023. VRE seemed to be quite stable over time with annual incidence rates ranging from 3.2 in 2017 to 4.2 in 2023; incidence rate was the highest in 2020 being equal to 4.7/100,000 inpatient days. CRKP decreased from 3.2/100,000 in 2017 to zero cases in 2021 and 2022, then rose to 1.9/100,000 in 2023. A statistically significant decreasing trend from 2017 to 2023 for MRSA and CRPA was observed (p < 0.05). Annual incidence rates of MDRO invasive infections by micro-organism; OPBG, 2017–2023 Discussion In this study, we have reported the epidemiology of MDR pathogens isolated from sterile sites in children hospitalized at an Italian tertiary pediatric hospital from 2017 to 2023. Our data show a proportion of positive cultures for selected bacteria, regardless of resistance profile, equal to 2.9%; overall, the proportion of MDROs was 13.8%. The observed prevalence of MDR pathogens differs from rates reported by other centers. A recent study conducted in a tertiary care hospital in Romania found an overall 30% of positivity rate for MDR pathogens [30]. This difference could be attributed to strict screening and isolation protocols adopted by our hospital and to local differences in the epidemiology of multidrug-resistant organisms [10]. Proportion of culture testing positive for MDROs differs among ward types being highest in Oncohematology (30.5%). Multi-drug resistant bacteria, especially Gram-negative bacteria, compromise treatment options and increase mortality in oncohematologic patients. The difficulty of documenting bacteraemia at the onset of fever in immunocompromised patients led to an early administration of broad-spectrum antibiotics, without waiting for further clinical or microbiological evidence of infection. This strategy aims to minimise the collateral damage associated with antibiotic overuse and selection of resistance [31]. We found a high proportion of MRSA (36.7%), especially isolated from blood. The prevalence of MRSA is similar to that reported in another study conducted in a pediatric hospital setting (30.0%) [32] and to the one recently estimated by the Antimicrobial Resistance Collaborators in Italy in 2019 (between 30 and 40%) [26]. We found a decreasing trend in both the proportion of MRSA isolates (from 43.5% in 2017 to 25.7% in 2023) and in the incidence of MRSA/100,000 patient days (from 14.3/100,000 patient days in 2017 to 10.2 /100,000 patient days in 2023). These results are in line with the decreasing trends of prevalence of MRSA (from 34.3 in 2019 to 26.6 in 2023) and of isolates from bloodstream infections in the Italian general population (from 13.4 in 2019 to 10.2 in 2023) reported by the European Centre for Disease Prevention and Control (ECDC) in the Annual Epidemiological Report for 2019–2023 [10]. Contrary to what was reported in the ECDC specific country report, we observed a significant decrease in the proportion and in the incidence of CRPA/PA. However, similar reductions during the COVID-19 period have been reported in a recent review of nine studies investigating the impact of the COVID-19 pandemic on CRPA further supports this observation [14]. Five of the studies reviewed reported a 10%–41% reduction in CRPA prevalence or incidence during the pandemic, including a 25% decrease in ICU settings. Although these studies were generally based on shorter observation periods, their findings are consistent with the decline in antimicrobial resistance of P. aeruginosa observed in our study. This reduction may also be partially explained by the decrease in hospital admissions observed during the COVID-19 pandemic. During 2020–2022, we observed lower proportions of several MDROs. While this pattern may reflect broader trends reported during the COVID-19 pandemic, multiple factors may have contributed to these observations, including changes in hospital admission patterns, healthcare utilization, case mix, culture-request practices, antimicrobial prescribing, and infection prevention and control measures. Indeed, several studies have documented a marked decline in pediatric healthcare utilization during this period, including substantial reductions in emergency department visits in Italy [33], particularly during the early pandemic phase, and decreases in hospital admissions across Europe [34] and the United States [35]. In our setting, MDRO proportions appeared to increase again after the pandemic period; in particular we found that the proportion of CRKP/KP, CRPA/PA in 2023 were higher with respect to 2019, except for MRSA/SA isolates that in 2023 was the half with respect to 2017–2019. VRE/E seemed not to be affected by pandemic period having a quite stable proportion of isolates along the entire period under study. Overall, interpretations of AMR trends during COVID-19 period remains challenging, as definitions and reporting vary widely across studies [36]. For example, data from the US Centers for Disease Control and Prevention found a 15% increase in the rate (per discharge or admission) of resistant organisms including carbapenem-resistant Acinetobacter, MRSA, CRE, and Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E) associated with the pandemic [37]. A recent meta-analysis reported that although the COVID-19 pandemic was not associated with a change in Gram-positive AMR, Gram-negative resistance may have increased (MDR or CRPA or carbapenem-resistant Acinetobacter spp., ESBL and CRE), particularly in settings where enhanced Infection Prevention and Control Activities and Antimicrobial stewardship programs were not reported [36]. Differences in study setting, local epidemiology, healthcare utilization, and prescribing patterns may partly explain discrepancies between our findings and those reported elsewhere. From a clinical perspective, our findings highlight that infection prevention and control measures and antimicrobial stewardship interventions can significantly influence the epidemiology of MDR pathogens [38]. The variability in MDRO distribution by ward and age group further underscores the need to tailor empirical antibiotic therapy according to patient population and clinical setting, supporting the adoption of ward-specific empirical treatment protocols. The marked reduction in CRPA during 2020–2021 supports the dynamic nature of antimicrobial resistance and its sensitivity to changes in healthcare organization [14]. These findings may inform antimicrobial stewardship programs by guiding more targeted empirical antibiotic choices and reinforcing the importance of continuous local surveillance data to support clinical decision-making. In addition, they highlight the potential value of adapting infection prevention strategies according to local epidemiology and patient case mix. Finally, the heterogeneous behaviour across pathogens suggests that pathogen-specific strategies, rather than uniform approaches, are required. Overall, these findings emphasize the importance of continuous surveillance and adaptable antimicrobial stewardship strategies, as recommended by international guidelines [39]. Strengths and limitations Despite the fact that this is a single-center study, it is worth mentioning its strength points. Firstly, this study provided a recent update on the status of the seriously alarming problem of MDROs in hospitalized children. Secondly, it provided updated information on the impact of MDROs to microbiologic culture and sensitivity data in a considerable number of patients, including different pediatric age groups (from neonates to adolescents) admitted to different type of wards with different levels of acuity of care (inpatient wards, NICU, and PICU). However, several limitations of this study should be acknowledged. First, this is a retrospective study conducted at a single center, which may limit the generalizability of the findings to other settings. In addition, the study lacks clinical outcome data, thus preventing evaluation of the clinical impact of MDRO infections. Possible changes over time in blood and CSF culture practices may also have influenced the observed trends. Furthermore, no data on patient colonization status were available, and therefore the relationship between colonization and invasive infection could not be assessed. The study has limited ability to distinguish true microbiological trends from potential changes in patient population characteristics or hospital activity over the study period. Finally, given the limited number of resistant isolates for some pathogens (e.g., CRKP), the resulting odds ratio estimates should be interpreted with caution, particularly when associated with wide confidence intervals, which reflect reduced stability and precision of the estimates. Conclusions In conclusion, understanding local epidemiology is essential for guiding empirical antibiotic treatment, as the incidence of causative pathogens can change over time and among hospital setting. Despite the low proportion of MDR pathogens identified in our series, the high percentage of ESKAPE pathogens underscore the necessity for continued screening and infection control measures, along with prudent use of antibiotics and accurate and up-to-date diagnostic testing [40]. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Abbreviations Antimicrobial resistance Multidrug resistance World Health Organization European Union Multidrug resistant microorganism Methicillin-resistant Staphylococcus aureus Carbapenems-resistant Klebsiella pneumonia Ospedale Pediatrico Bambino Gesù Carbapenem-Resistant Enterobacteriaceae Emergency Department Cerebrospinal Fluid Staphylococcus aureus Klebsiella pneumoniae Pseudomonas aeruginosa Acinetobacter baumanii Enterococcus Carbapenem-Resistant Acinetobacter baumannii Carbapenem-Resistant Enterobacter cloacae Carbapenem-Resistant Klebsiella pneumoniae Carbapenem-Resistant Pseudomonas aeruginosa Vancomycin-Resistant Enterococcus Minimum Inhibitory Concentration Extensively Drug‑Resistant Pseudomonas aeruginosa Extensively Drug‑Resistant Acinetobacter baumanii Multi‑Drug Resistant Pseudomonas aeruginosa Multi‑Drug Resistant Acinetobacter baumanii Neonatal Intensive Care Unit Pediatric Intensive Care Unit Odds Ratio Confidence Interval European Centre for Disease Prevention and Control Extended‑Spectrum Beta‑Lactamase–Producing Enterobacterales Author contributions MCDA and MR developed the concept. CDA, PB and GC collected data. FB performed the data analysis. CDA and FB wrote the draft of the manuscript. CDA, FB, LV, BZ, EC, LR and MCDA interpreted the data. All authors reviewed the final manuscript. Funding This work was supported by the Italian Ministry of Health with “Current Research funds”, by the European Commission within the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT) and by a “5 per mille” funded project entitled “Clinical evaluation of healthcare technologies and interventions aimed at reducing the risk of healthcare-associated infections in pediatrics”. Data availability The datasets generated and/or anaysed during the current study are not publicly available due to reasons of sensitivity but are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study was approved by the Ethics Committee of the Bambino Gesù Children’s Hospital (3203_OPBG_2023). The need for informed consent was waived by the Ethical Committee of the Bambino Gesù Children’s Hospital. Competing interests The authors declare that they have no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets generated and/or anaysed during the current study are not publicly available due to reasons of sensitivity but are available from the corresponding author on reasonable request.